Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: Modulation by antiretroviral treatment, HIV replication and HCV co-infection

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Beltrán, Luis M ^a,b   Muñoz Hernández, Rocío ^a   De Pablo Bernal, Rebeca S ^a   García Morillo, José S ^a   Egido, Jesús ^c,d   Noval, Manuel Leal ^a   Ferrando Martinez, Sara ^a,e,f,g   Blanco Colio, Luis M ^c   Genebat, Miguel ^a   Villar, José R ^a   Moreno Luna, Rafael ^a,h   Moreno, Juan Antonio ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^h HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CD163 ANTIGEN; D DIMER; INTERLEUKIN 6; MARAVIROC; N(G),N(G) DIMETHYLARGININE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; THROMBOSIS; TREATMENT DURATION; VIRUS REPLICATION;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARGININE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COINFECTION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; TUMOR NECROSIS FACTORS; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT;

EID: 84897053488     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090541     Document Type: Article

References (58)

1. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, et al. (2010) Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 55: 262-70.
2. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, et al. (2008) Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 118: e29-35.
3. Triant VA, Lee H, Hadigan C, Grinspoon SK (2007) Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 92: 2506-12. (Pubitemid 47037350)
4. Baker JV, Lundgren JD (2011) Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 32: 945-51.
5. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283-96. (Pubitemid 44837777)
6. Dubé MP, Lipshultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, et al. (2008) Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 118: e36-40.
7. Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, et al. (2006) The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 7: 218-30.
8. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, et al. (1997) TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272: 32401-10. (Pubitemid 28011923)
9. Blanco-Colio LM, Martín-Ventura JL, Munoz-Garcia B, Moreno JA, Meilhac O, et al. (2007) TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. Front Biosci 12: 3648-55.
10. Nakayama M, Harada N, Okumura K, Yagita H (2003) Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun 306: 819-25. (Pubitemid 36776204)
11. Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y, et al. (2004) TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 68: 396-9. (Pubitemid 38470720)
12. Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, et al. (2010) Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol 30: 1253-62.
13. Jelić-Ivanović Z, Bujisić N, Spasić S, Bogavac-Stanojević N, Spasojević-Kalimanovska V, et al. (2009) Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem 42: 1381-6.
14. Blanco-Colio LM, Martín-Ventura JL, Muñóz- García B, Orbe J, Páramo JA, et al. (2007) Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 27: 916-22. (Pubitemid 46606725)
15. Martín-Ventura JL, Lindholt JS, Moreno JA, Vega de Céniga M, Meilhac O, et al. (2011) Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis 214: 486-9.
16. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lössner U, et al. (2008) Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 199: 440-4. (Pubitemid 352020411)
17. Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Bárány P, et al. (2009) Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 4: 110-8.
18. Valdivielso JM, Coll B, Martín-Ventura JL, Moreno JA, Egido J, et al. (2013) Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. J Nephrol 26: 1105-13.
19. Chorianopoulos E, Rosenberg M, Zugck C, Wolf J, Katus HA, et al. (2009) Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail 11: 1050-6.
20. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, et al. (2010) Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 211: 322-6.
21. Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, et al. (2011) Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol 6: 785-92.
22. Urbonaviciene G, Martin-Ventura JL, Lindholt JS, Urbonavicius S, Moreno JA, et al. (2011) Impact of soluble TWEAK and CD163/TWEAK ratio on longterm cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis 219: 892-9.
23. Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, et al. (2007) A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 178: 8183-94. (Pubitemid 46898091)
24. Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, et al. (2009) The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 207: 103-10.
25. Møller HJ, Peterslund NA, Graversen JH, Moestrup SK (2002) Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 99: 378-80. (Pubitemid 34533008)
26. Davis BH, Zarev PV (2005) Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom 63: 16-22. (Pubitemid 40096840)
27. Moreno JA, Ortega-Gómez A, Delbosc S, Beaufort N, Sorbets E, et al. (2012) In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis. Eur Heart J 33: 252-63.
28. Aristoteli LP, Møller HJ, Bailey B, Moestrup SK, Kritharides L (2006) The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 184: 342-7. (Pubitemid 43049718)
29. Levy AP, Purushothaman KR, Levy NS, Purushothaman M, Strauss M, et al. (2007) Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque haemorrhage and plaque vulnerability. Circ Res 101: 106-10. (Pubitemid 47094629)
30. Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, et al. (2011) Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis 204: 154-63.
31. Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, et al. (2011) Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 204: 1227-36.
32. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, et al. (2012) Arterial inflammation in patients with HIV. JAMA 308: 379-86.
33. Panel de expertos de Gesida y Plan Nacional sobre el Sida (2012) [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)]. Enferm Infecc Microbiol Clin 30:e1-89.
34. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, et al. (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 201: 1788-95.
35. Kurz K, Teerlink T, Sarcletti M, Weiss G, Zangerle R, et al. (2009) Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers. Pharmacol Res 60: 508-14.
36. Calza L, Pocaterra D, Pavoni M, Colangeli V, Manfredi R, et al. (2009) Plasma levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. J Acquir Immune Defic Syndr 50: 430-2.
37. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5: e203.
38. Triant VA, Meigs JB, Grinspoon SK (2009) Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 51: 268-73.
39. Kalayjian RC, Machekano RN, Rizk N, Robbins GK, Gandhi RT, et al. (2010) Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis 201: 1796-805.
40. Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, et al. (2009) Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 49: 1119-27.
41. Jang JJ, Berkheimer SB, Merchant M, Krishnaswami A (2011) Asymmetric dimethylarginine and coronary artery calcium scores are increased in patients infected with human immunodeficiency virus. Atherosclerosis 217: 514-7.
42. Muñoz-García B, Moreno JA, López-Franco O, Sanz AB, Martín-Ventura JL, et al. (2009) Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoEknockout mice. Arterioscler Thromb Vasc Biol 29: 2061-8.
43. Muñoz-García B, Martín-Ventura JL, Martínez E, Sánchez S, Hernández G, et al. (2006) Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 37: 2044-53. (Pubitemid 44309902)
44. Fick A, Lang I, Schäfer V, Seher A, Trebing J, et al. (2012) Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J Biol Chem. 287:484-95.
45. Tippett E, Cheng WJ, Westhorpe C, Cameron PU, Brew BJ, et al. (2011) Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS One 6: e19968.
46. Hearps AC, Maisa A, Cheng WJ, Angelovich TA, Lichtfuss GF, et al. (2012) HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 26: 843-53.
47. Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, et al. (2009) Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med 10: 79-87.
48. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, et al. (2012) Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 26: 1371-85.
49. Funderburg NT, Andrade A, Chan ES, Rosenkranz SL, Lu D, et al. (2013) Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine. PLoS One 8: e83514.
50. Jong E, Louw S, van Gorp EC, Meijers JC, ten Cate H, et al. (2010) The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. Thromb Haemost 104: 1228-34.
51. Baker JV, Neuhaus J, Duprez D, Freiberg M, Bernardino JI, et al. (2012) HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. J Acquir Immune Defic Syndr 60: 128-34.
52. Martin GE, Gouillou M, Hearps AC, Angelovich TA, Cheng AC, et al. (2013) Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One 8: e55279.
53. Sandler NG, Sereti I (2014) Can early therapy reduce inflammation? Curr Opin HIVAIDS 9: 72-9.
54. Hsue PY, Scherzer R, Hunt PW, Schnell A, Bolger AF, et al. (2012) Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. J Am Heart Assoc pii: jah3-e000422.
55. Islam FM, Wu J, Jansson J, Wilson DP (2012) Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med 13: 453-468.
56. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, et al. (2001) Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104: 257-62. (Pubitemid 32666944)
57. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, et al. (2010) Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 201: 318-30.
58. Sosner P, Wangermez M, Chagneau-Derrode C, Le Moal G, Silvain C (2012) Atherosclerosis risk in HIV-infected patients: the influence of hepatitis C virus co-infection. Atherosclerosis 222: 274-7.